DPP-4抑制剂在2型糖尿病中的研究进展
Research Progress of DPP-4 Inhibitors in Type 2 Diabetes Mellitus
DOI: 10.12677/ns.2025.147172, PDF,   
作者: 刘 玲, 陈 磊, 彭渝涵, 沈怡帆：贵州中医药大学护理学院，贵州 贵阳；冷 羽*, 李 志：贵州中医药大学第一附属医院，贵州 贵阳
关键词: DPP-4抑制剂；二肽基肽酶抑制剂；2型糖尿病；DPP-4 Inhibitor； Dipeptidyl Peptidase Inhibitor； Type 2 Diabetes Mellitus
摘要: 本文综述了二肽基肽酶-4 (DPP-4)抑制剂在2型糖尿病(T2DM)治疗中的临床应用及其研究进展。DPP-4抑制剂通过抑制DPP-4酶活性，提高内源性胰高血糖素样肽-1 (GLP-1)水平，进而促进胰岛素分泌、抑制胰高血糖素释放，实现有效降低血糖。本文探讨了DPP-4抑制剂的作用机制、临床应用效果、安全性及未来研究方向，旨在为T2DM的治疗提供新的思路。
Abstract: This article reviews the clinical application and research progress of dipeptidyl peptidase-4 (DPP-4) inhibitors in the treatment of type 2 diabetes mellitus (T2DM). DPP-4 inhibitors can increase the level of endogenous glucagon like peptide-1 (GLP-1) by inhibiting DPP-4 enzyme activity, thereby promoting insulin secretion, inhibiting glucagon release, and effectively reducing blood glucose. This article discusses the mechanism of action, clinical application effect, safety and future research direction of DPP-4 inhibitors, aiming to provide new ideas for the treatment of T2DM.
文章引用：刘玲, 冷羽, 李志, 陈磊, 彭渝涵, 沈怡帆. DPP-4抑制剂在2型糖尿病中的研究进展[J]. 护理学, 2025, 14(7): 1297-1303. https://doi.org/10.12677/ns.2025.147172

参考文献

[1] Wulandari, N., Lamuri, A., van Hasselt, F., Feenstra, T. and Taxis, K. (2025) The Burden of Depression among Patients with Type 2 Diabetes: An Umbrella Review of Systematic Reviews. Journal of Diabetes and Its Complications, 39, Article ID: 109004. [Google Scholar] [CrossRef] [PubMed]
[2] Muscogiuri, G., Caporusso, M., Caruso, P., Poggi, C.D., Vitale, M., Zurru, A., et al. (2024) Current Evidence on Gender-Related Risk Factors for Type 1 Diabetes, Type 2 Diabetes and Prediabetes: A Reappraisal of the Italian Study Group on Gender Difference in Endocrine Diseases. Journal of Endocrinological Investigation, 48, 573-585. [Google Scholar] [CrossRef] [PubMed]
[3] Chen, Y., Jiang, Q., Xing, X., Yuan, T. and Li, P. (2024) Clinical Research Progress on β-Cell Dysfunction in T2DM Development in the Chinese Population. Reviews in Endocrine and Metabolic Disorders, 26, 31-53. [Google Scholar] [CrossRef] [PubMed]
[4] 周牡娜, 肖军, 欧阳方丹, 等. 六味地黄提取物调控胰高血糖素样肽-1的“肠促胰素效应”对2型糖尿病大鼠的影响[J/OL]. 中药药理与临床, 2025: 1-13. 2025-03-19.[CrossRef] 
[5] 罗樱樱, 吴光雨, 纪立农. 葡萄糖依赖性促胰岛素多肽/胰高血糖素样肽1受体激动剂Tirzepatide对心血管系统作用的研究进展[J]. 中国糖尿病杂志, 2024, 32(9): 715-720.
[6] 杨杰, 刘大成. 胰岛素泵强化降糖与DPP-Ⅳ抑制剂改善2型糖尿病患者胰岛β细胞功能的研究进展[J]. 社区医学杂志, 2015, 13(13): 28-32.
[7] 陈韬, 曹建民. 餐前负荷中食用蔬菜汁对餐后血糖和胰岛素水平的影响[C]//中国营养学会, 中国疾病预防控制中心营养与健康所, 农业农村部食物与营养发展研究所, 中国科学院上海营养与健康研究所, 华中科技大学公共卫生学院. 中国营养学会第十五届全国营养科学大会论文汇编. 2022: 183.
[8] 郭亚菊, 张勇军, 宋书贤, 等. 二肽基肽酶-Ⅳ抑制剂对自发性2型糖尿病大鼠血清GLP-1和GIP的影响及调控机制[J]. 临床和实验医学杂志, 2018, 17(21): 2260-2265.
[9] 谢淑贤, 刘蕾, 唐海. 替格列汀在2型糖尿病特殊人群中用药优势的研究进展[J]. 现代药物与临床, 2023, 38(9): 2368-2373.
[10] 汪磊, 杨智荟, 郑洋, 等. 二肽基肽酶4的多功能性及相关药物靶点作用机制的研究进展[J/OL]. 中国药理学通报, 1-6.
http://kns.cnki.net/kcms/detail/34.1086.r.20240920.1613.010.html, 2024-10-22.
[11] 路璐. DPP-4抑制剂对心肌缺血再灌注损伤的作用及机制研究[D]: [硕士学位论文]. 西安: 西安医学院, 2020.
[12] 陈伟林, 林小燕. 基础胰岛素联合DPP4抑制剂或磺脲类药物在糖尿病肾病患者血糖控制中的疗效与安全性分析[J]. 世界复合医学, 2020, 6(7): 167-168+171.
[13] 何筱莹, 李延兵. DPP-4抑制剂的降糖作用机制[J]. 药品评价, 2012, 9(34): 17-19+23.
[14] 高广艺. DPP-4抑制剂治疗2型糖尿病患者的短期疗效及其影响因素的分析[D]: [硕士学位论文]. 长春: 吉林大学, 2019.
[15] 谷志超, 曲超, 石岩, 等. DPP4抑制剂与中医药防治糖尿病视网膜病变研究进展[J]. 辽宁中医药大学学报, 2021, 23(9): 194-197.
[16] 杨莉, 张大伟. 吡格列酮二甲双胍联合DPP4抑制剂对2型糖尿病患者血糖控制及体态的影响[J]. 河北医药, 2022, 44(23): 3626-3629.
[17] 李益明. DPP-4抑制剂的独特作用机制: 胰岛α、β细胞双调节作用[J]. 药品评价, 2014, 11(7): 21-25.
[18] 王汝龙, 母义明, 胡欣. 2型糖尿病治疗的新选择——DPP-4抑制剂[J]. 中国药学杂志, 2014, 49(8): 702-704.
[19] Sotoudeheian, M., Mirahmadi, S., Salehi Darjani, P., Moradi, M., Pirhayati, M., Dakkali, M.S., et al. (2025) Sitagliptin, Diabetes Mellitus, and Heart Failure: An In-Depth Review of Sitagliptin Therapy and Heart Failure in Patients with Diabetes Mellitus. Diabetology International, 16, 237-256. [Google Scholar] [CrossRef] [PubMed]
[20] Zong, Y., Wang, X., Zhang, Y., Tan, N., Zhang, Y., Li, L., et al. (2023) Sitagliptin Ameliorates Creb5/lncRNA Ensmust00000213271-Mediated Vascular Endothelial Dysfunction in Obese Mice. Cardiovascular Drugs and Therapy, 38, 679-691. [Google Scholar] [CrossRef] [PubMed]
[21] Hwang, H., Jung, T.W., Kim, B., Hong, H.C., Seo, J.A., Kim, S.G., et al. (2015) A Dipeptidyl Peptidase-IV Inhibitor Improves Hepatic Steatosis and Insulin Resistance by AMPK-Dependent and JNK-Dependent Inhibition of LECT2 Expression. Biochemical Pharmacology, 98, 157-166. [Google Scholar] [CrossRef] [PubMed]
[22] Scirica, B.M., Bhatt, D.L., Braunwald, E., Steg, P.G., Davidson, J., Hirshberg, B., et al. (2013) Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. New England Journal of Medicine, 369, 1317-1326. [Google Scholar] [CrossRef] [PubMed]
[23] White, W.B., Cannon, C.P., Heller, S.R., Nissen, S.E., Bergenstal, R.M., Bakris, G.L., et al. (2013) Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. New England Journal of Medicine, 369, 1327-1335. [Google Scholar] [CrossRef] [PubMed]
[24] Yang, Y., Kornelius, E., Wang, Y., Lo, S. and Huang, C. (2024) Association of Dipeptidyl Peptidase-4 Inhibitor and Recurrent Pancreatitis Risk among Patients with Type 2 Diabetes: A Retrospective Cohort Study. Frontiers in Pharmacology, 15, Article ID: 1341363. [Google Scholar] [CrossRef] [PubMed]
[25] Lee, M., Sun, J., Han, M., Cho, Y., Lee, J., Nam, C.M., et al. (2019) Nationwide Trends in Pancreatitis and Pancreatic Cancer Risk among Patients with Newly Diagnosed Type 2 Diabetes Receiving Dipeptidyl Peptidase 4 Inhibitors. Diabetes Care, 42, 2057-2064. [Google Scholar] [CrossRef] [PubMed]
[26] Chai, S., Liu, F., Yang, Z., Yu, S., Liu, Z., Yang, Q., et al. (2022) Risk of Fracture with Dipeptidyl Peptidase-4 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, or Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-Analysis Combining 177 Randomized Controlled Trials with a Median Follow-Up of 26 Weeks. Frontiers in Pharmacology, 13, Article ID: 825417. [Google Scholar] [CrossRef] [PubMed]
[27] Yang, J., Huang, C., Wu, S., Xu, Y., Cai, T., Chai, S., et al. (2017) The Effects of Dipeptidyl Peptidase-4 Inhibitors on Bone Fracture among Patients with Type 2 Diabetes Mellitus: A Network Meta-Analysis of Randomized Controlled Trials. PLOS ONE, 12, e0187537. [Google Scholar] [CrossRef] [PubMed]

为你推荐